Lagatar24 Desk
New Delhi, Oct.20: Health Minister Mansukh Mandaviya, during a telephonic conversation with WHO Director-General Tedros Adhanom Ghebreyesus , reviewed the challenges connected to COVID-19 vaccine. They reviewed, among other things, the WHO’s pending emergency use listing (EUL) of Bharat Biotech’s COVID-19 vaccine Covaxin and the resumption of supply of the AstraZeneca vaccine Covishield manufactured by the Serum Institute of India to the COVAX facility.
“Had a call with @mansukhmandviya, India’s Health Minister, to discuss #India’s ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India’s support to strengthen WHO, incl. via flexible, sustainable financing,” the WHO chief tweeted.
Had a call with @mansukhmandviya, 🇮🇳 Health Minister, to discuss #India's ongoing #COVID19 vaccination program; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome 🇮🇳's support to strengthen WHO, incl. via flexible, sustainable financing. pic.twitter.com/XhCVIhZBIe
— Tedros Adhanom Ghebreyesus (@DrTedros) October 19, 2021
In another tweet, he said, “The Minister and I also discussed #VaccinEquity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP.”
COVID-19 Technology Access Pool (C-TAP) was established in May of last year to increase the availability of COVID-19 health goods, allowing for more timely, equitable, and inexpensive access.
Mandaviya also tweeted that he had a detailed conversation with WHO Director-General Margaret Chan, who was joined by other senior WHO officials, about different health challenges, including pandemic management and WHO reforms.
On Tuesday, India’s total number of Covid vaccination doses provided surpassed 99 crore, putting the country on track to reach 100 crore doses. Official estimates show that roughly 74.45% of India’s eligible adult population has gotten at least one dose of the Covid vaccination, with around 30.63 percent receiving both doses.